HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Indomethacin treatment prevents high fat diet-induced obesity and insulin resistance but not glucose intolerance in C57BL/6J mice.

Abstract
Chronic low grade inflammation is closely linked to obesity-associated insulin resistance. To examine how administration of the anti-inflammatory compound indomethacin, a general cyclooxygenase inhibitor, affected obesity development and insulin sensitivity, we fed obesity-prone male C57BL/6J mice a high fat/high sucrose (HF/HS) diet or a regular diet supplemented or not with indomethacin (±INDO) for 7 weeks. Development of obesity, insulin resistance, and glucose intolerance was monitored, and the effect of indomethacin on glucose-stimulated insulin secretion (GSIS) was measured in vivo and in vitro using MIN6 β-cells. We found that supplementation with indomethacin prevented HF/HS-induced obesity and diet-induced changes in systemic insulin sensitivity. Thus, HF/HS+INDO-fed mice remained insulin-sensitive. However, mice fed HF/HS+INDO exhibited pronounced glucose intolerance. Hepatic glucose output was significantly increased. Indomethacin had no effect on adipose tissue mass, glucose tolerance, or GSIS when included in a regular diet. Indomethacin administration to obese mice did not reduce adipose tissue mass, and the compensatory increase in GSIS observed in obese mice was not affected by treatment with indomethacin. We demonstrate that indomethacin did not inhibit GSIS per se, but activation of GPR40 in the presence of indomethacin inhibited glucose-dependent insulin secretion in MIN6 cells. We conclude that constitutive high hepatic glucose output combined with impaired GSIS in response to activation of GPR40-dependent signaling in the HF/HS+INDO-fed mice contributed to the impaired glucose clearance during a glucose challenge and that the resulting lower levels of plasma insulin prevented the obesogenic action of the HF/HS diet.
AuthorsEven Fjære, Ulrike L Aune, Kristin Røen, Alison H Keenan, Tao Ma, Kamil Borkowski, David M Kristensen, Guy W Novotny, Thomas Mandrup-Poulsen, Brian D Hudson, Graeme Milligan, Yannan Xi, John W Newman, Fawaz G Haj, Bjørn Liaset, Karsten Kristiansen, Lise Madsen
JournalThe Journal of biological chemistry (J Biol Chem) Vol. 289 Issue 23 Pg. 16032-45 (Jun 06 2014) ISSN: 1083-351X [Electronic] United States
PMID24742673 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
Copyright© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.
Chemical References
  • Cyclooxygenase Inhibitors
  • Fatty Acids, Nonesterified
  • Inflammation Mediators
  • Oxylipins
  • Glycerol
  • Indomethacin
Topics
  • Animals
  • Cell Line
  • Cyclooxygenase Inhibitors (pharmacology)
  • Diet, High-Fat
  • Fatty Acids, Nonesterified (blood)
  • Glucose Tolerance Test
  • Glycerol (blood)
  • Indomethacin (pharmacology)
  • Inflammation Mediators (blood)
  • Insulin Resistance
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Obesity (prevention & control)
  • Oxylipins (blood)
  • Real-Time Polymerase Chain Reaction

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: